Demonstrate how AI-driven initiatives - like predictive modelling and automated inspection -translate into measurable outcomes (e.g., defect reduction, shorter batch release cycles) that justify capital investment and cross-functional prioritization.

Learn how predictive simulations, generative AI and differentiating clinical biomarkers are forecasted to cut prototyping timelines by weeks and reduce per‑trial costs.

.

Empowers strategic R&D with AI-driven predictive modelling early in discovery, fostering a data-driven culture.

Learn how  GenAI is transforming early drug discovery by designing novel, drug-like small molecules with improved potency, selectivity, and ADME properties.
Explore how GenAI integrates with synthesis planning and automation tools to prioritize viable candidates and accelerate iterative drug development.

Discuss how AI is used to identify pathological features, discover drug targets, and decode complex disease biology at a systems level.